Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 13/20 | 0.35 |
| ▸ | PGR | P06401 | 3/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.31 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19643519 | 1.00 | AR (0.35) | ARPGRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21028817 | 0.81 | AR (0.37) | ARPGR | |
| SCHEMBL19643008 | 0.80 | PGR (0.38) | ARPGRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19641872 | 0.80 | PGR (0.38) | ARPGRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31585416 | 0.78 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25356465 | 0.77 | KDM4E (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25356462 | 0.77 | KDM4E (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19643694 | 0.76 | SLC6A2 (0.37) | ARPGRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19643696 | 0.76 | SLC6A2 (0.37) | ARPGRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28567534 | 0.75 | PGR (0.48) | ARPGRSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161819-B2 | Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists | MERCK SHARP & DOHME CORP. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200347020-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-11-05 | — | — | US | disclosed |
| US-20190161448-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-05-30 | — | — | US | disclosed |
| EP-3463362-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | Merck Sharp & Dohme Corp. (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017205193-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161448-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | GPR119, GPR88, GPR180 | AR 565/4885PGR 1294/4885SLC6A2 1806/4885 |
| US-11161819-B2 | Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists | GPR119, GPR88, GPR180 | AR 496/4885PGR 1257/4885SLC6A2 1574/4885 |
| US-20200347020-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | GPR119, GPR88, GPR180 | AR 496/4885PGR 1257/4885SLC6A2 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.